Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Spatial Allocation of Scarce COVID-19 Vaccines

View ORCID ProfileFrançois M. Castonguay, View ORCID ProfileJulie C. Blackwood, View ORCID ProfileEmily Howerton, View ORCID ProfileKatriona Shea, View ORCID ProfileCharles Sims, View ORCID ProfileJames N. Sanchirico
doi: https://doi.org/10.1101/2020.12.18.20248439
François M. Castonguay
§Department of Agricultural and Resource Economics, University of California, Davis, Davis, CA 95616, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for François M. Castonguay
  • For correspondence: fcastonguay@ucdavis.edu
Julie C. Blackwood
¶Department of Mathematics and Statistics, Williams College, Williamstown, MA 01267, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julie C. Blackwood
Emily Howerton
‖Department of Biology and Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emily Howerton
Katriona Shea
‖Department of Biology and Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katriona Shea
Charles Sims
**Howard H. Baker Jr. Center for Public Policy and Department of Economics, University of Tennessee, Knoxville, Knoxville, TN 37996, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles Sims
James N. Sanchirico
‡‡Department of Environmental Science and Policy, University of California, Davis, Davis, CA 95616, USA and Resources for the Future, Washington DC 20036, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James N. Sanchirico
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Although the COVID-19 disease burden is heterogeneous across space, the U.S. National Academies of Sciences, Engineering, and Medicine recommends an equitable spatial allocation of vaccines based, for example, on population size, in the interest of speed and workability. Utilizing economic–epidemiological modeling, we benchmark the performance of this ad hoc allocation rule by comparing it to the rule that minimizes the economic damages and expenditures over time, including a penalty cost representing the social costs of deviating from ad hoc allocations that favor speed and workability. Under different levels of vaccine scarcity and different demographic characteristics, we consider scenarios where length of immunity and compliance to travel restrictions vary, and consider the robustness of the rules when assumptions regarding these factors are incorrect. The benefits from deviating are especially high when immunity is permanent, when there is compliance to travel restrictions, when the supply of vaccine is low, and when there is heterogeneity in demographic characteristics. Interestingly, a lack of compliance to travel restrictions pushes the optimal allocations of vaccine towards the ad hoc and improves the relative robustness of the ad hoc rules, as the mixing of the populations reduces the spatial heterogeneity in disease burden.

JEL Classification C61, H12, H84, I18, Q54

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

F.M.C. acknowledges funding from the Henry A. Jastro Graduate Research Scholarship Award. K.S and E.H. acknowledge funding from the Huck Institutes for the Life Sciences at The Pennsylvania State University. J.N.S. is a member of the Giannini Foundation of Agricultural Economics and acknowledges support from National Institute of Food and Agriculture (CA-D-ESP-7853-H).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No human or animal subjects were involved in this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • † We thank for useful comments participants of the NatuRE Policy Lab at UC Davis (naturepolicy.ucdavis.edu), as well as participants of the internal seminars of the Department of Economics at Université du Québec à Montréal (UQAM), and those of the Montreal Environment and Resource Economics Workshop.

  • ‡ For the code used in this paper, see: https://github.com/fmcastonguay/SpatialAllocationCOVID19

  • Removed the section on antivirals and focussed the discussion more around vaccines and heterogeneous demographic characteristics.

  • 6 Calibrated using a R0 estimate from Li et al. [4] and estimates of effects of nonpharmaceutical interventions from Tian et al. [5]; this yields a R0 of approximately 1.4 when there is compliance to travel restrictions and to match a R0 of approximately 2.1 when there is no compliance to travel restrictions; these two values representing respectively a “medium” and “low” effect of the nonpharmaceutical intervention.

  • 7 Using estimates from Davies et al. [6]; this represents a 3-day latency period and a 5-day recovery period.

  • 8 Representing a 6-month immunity period in the scenarios where we assume immunity is not permanent; based on [13].

  • 9 Calibrated by using a case-fatility rate of 1.78%. Adjusted for mis- and under-reporting; see [7].

  • 10 Representing the disability associated with severe lower respiratory tract infections because, to our knowledge, there are no official disability estimates associated with COVID-19; see [10].

  • 11 Following Buckner et al. [14], we base this parameter value on the efficiency of the influenza vaccine [15]. Note that the Department of Health and Human Services, Food and Drug Administration (FDA), and Center for Biologics Evaluation and Research (CBER) [16] requires that a future COVID-19 vaccine must have an effectiveness of at least 50%.

  • 12 Based on results from John et al. [12] that suggest a yearly discount rate between 0.3% and 1.5% for health related expenditures; we chose a 1.5% annual discount rate in the main set of results. This gives a monthly discount rate of r = 0.0013.

  • 13 Assuming an individual requires two doses; based on current agreements between the U.S. federal government and biotech companies; see https://www.npr.org/sections/health-shots/2020/08/06/899869278/prices-for-covid-19-vaccines-are-starting-to-come-into-focus. For a list of current vaccine prices, and particularly the price of the influenza vaccine, see https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html.

  • 14 Value based on a certain proportion of the value of statistical life, c; in the base case we assume it is 2 orders of magnitude smaller.

  • 15 Represents a value of statistical life of 10M U.S. dollars. Based on the value of a statistical life that the U.S. Environmental Protection Agency [9] uses: approximately $7.4 million ($2006) which is equivalent to approximately $9.54 million ($2020).

Data Availability

The parameter values used to run the numerical simulations are publicly available from the citations included in the text.

https://github.com/fmcastonguay/SpatialAllocationCOVID19

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Spatial Allocation of Scarce COVID-19 Vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Spatial Allocation of Scarce COVID-19 Vaccines
François M. Castonguay, Julie C. Blackwood, Emily Howerton, Katriona Shea, Charles Sims, James N. Sanchirico
medRxiv 2020.12.18.20248439; doi: https://doi.org/10.1101/2020.12.18.20248439
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Spatial Allocation of Scarce COVID-19 Vaccines
François M. Castonguay, Julie C. Blackwood, Emily Howerton, Katriona Shea, Charles Sims, James N. Sanchirico
medRxiv 2020.12.18.20248439; doi: https://doi.org/10.1101/2020.12.18.20248439

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)